Elevation Oncology: Promising Cancer Therapies Earn Analyst Praise
Elevation Oncology: Promising Cancer Therapies Earn Analyst Praise
This protein is typically hidden in healthy tissues but becomes accessible and overexpressed in many cancers, making it an ideal therapeutic focus.William Blair initiated coverage on Elevation Oncology, Inc. (NASDAQ:ELEV), a cancer drug focus firm leveraging antibody-drug conjugate expertise initially targeting two clinically validated targets in oncology, Claudin 18.2 and HER3.
威廉·布莱尔开始对Elevation Oncology, Inc.（纳斯达克：ELEV）进行覆盖，这是一个专注于癌症药物的公司，利用抗体药物结合体的专业知识，最初针对两个在肿瘤学中已经验证的靶点，Claudin 18.2和HER3。
Analyst Andy Hsieh writes that investing in Elevation Oncology offers a favorable risk-to-reward ratio, especially at its current valuation. He has initiated coverage with an Outperform rating.
分析师Andy Hsieh表示，投资Elevation Oncology提供了有利的风险回报比，尤其是在目前的估值下。他已对其发起覆盖，并给予优于大盘的评级。
The company provides exposure to the fast-growing market of antibody-drug conjugates and focuses on a scientifically and regulatory-validated target. The ADC field has gained significant interest, with claudin 18.2 emerging as a promising target.
该公司为抗体药物结合体的快速增长市场提供了投资机会，并专注于一个科学和监管上已被验证的靶点。抗体药物结合体领域引起了显著关注，Claudin 18.2作为一个前景广阔的靶点正在崭露头角。
This protein is typically hidden in healthy tissues but becomes accessible and overexpressed in many cancers, making it an ideal therapeutic focus.
这种蛋白质通常隐藏在健康组织中，但在许多癌症中变得可接近并过度表达，使其成为理想的治疗靶点。
Elevation's lead program, EO-3021, aligns with these trends and has shown promising results in early Phase I trials. Additionally, the recent approval of Astellas Pharma Inc's (OTC:ALPMF) (OTC:ALPMY) Vyloy, a CLDN18.2-targeted antibody, reduces clinical and regulatory risks for Elevation's program, offering high potential rewards for a modest initial investment.
Elevation的主要项目EO-3021与这些趋势相吻合，并在早期一期试验中显示出有希望的结果。此外，安斯泰莱制药（ADR）最近批准了Vyloy，这是一种针对CLDN18.2的抗体，降低了Elevation项目的临床和监管风险，为适度的初始投资提供高潜在回报。
In August, Elevation Oncology reported initial data from the dose escalation portion of the ongoing Phase 1 trial of EO-3021.
在8月份，Elevation Oncology报告了正在进行的EO-3021一期试验的剂量递增部分的初步数据。
As of the data cutoff date of June 10, 32 patients had been treated. EO-3021 was observed to be generally well-tolerated. No Grade 4 or 5 treatment-related adverse events were reported, and less than 10% of patients discontinued EO-3021 due to adverse events.
截至截止日期2023年6月10日，已有32名患者接受了治疗。EO-3021被观察为一般耐受良好。没有报告4级或5级治疗相关的不良事件，且不到10%的患者因不良事件中止使用EO-3021。
Hsieh estimates the total addressable market for frontline CLDN18.2-positive gastric and GEJ cancer in five major regions at about $6.6 billion, with $1.8 billion in the U.S. alone.
Hsieh估计，五个主要地区的前线CLDN18.2阳性胃癌和GEJ癌症的可寻址市场总额约为66亿元，其中美国独占18亿元。
For second-line pancreatic cancer, which has limited treatment options, the TAM is projected at $1.8 billion across the U.S. and Europe, including $1.3 billion in the U.S. The analysts believe even a small market share in these areas could significantly boost the company's current valuation.
对于第二线胰腺癌，治疗选择有限，预计在美国和欧洲的市场规模为18亿美元，其中美国为13亿美元。分析师认为，即使在这些领域占据小份额也能显著提升公司的当前估值。
Recently, Elevation Oncology nominated EO-1022 as its HER3 ADC development candidate. EO-1022 is progressing through preclinical development, and Elevation Oncology expects to file an investigational new drug application in 2026.
最近，Elevation Oncology提名EO-1022作为其HER3 ADC开发候选药物。EO-1022正在进行临床前开发，Elevation Oncology预计将在2026年提交一项研究新药申请。
Price Action: ELEV stock is up 7.54% at $0.64 at last check Friday.
价格走势：截至上周五，ELEV股票上涨7.54%，报0.64美元。
- Biden Blocks $14.9B US Steel Takeover, Shares Plunge (UPDATED)
- 拜登阻止了149亿美元的美国钢铁收购，股价暴跌（更新）
Photo: Shutterstock
Photo: shutterstock
